BPC 157: How a Stomach Peptide May Heal Injuries Across the Body by Controlling Blood Vessel Function
BPC 157, a 15-amino-acid peptide found naturally in human stomach juice, demonstrates broad healing properties by protecting cells, blood vessel linings, and actively directing blood flow toward injuries.
Quick Facts
What This Study Found
BPC 157, a pentadecapeptide (15 amino acids) native to human gastric juice, demonstrated a three-part cytoprotective mechanism: (1) stomach cell protection, (2) endothelium (blood vessel lining) protection, and (3) active blood vessel function control. After perforating injuries, BPC 157 activated blood vessels to grow toward the defect. After vessel obstruction, it activated collateral vessels to bypass the blockage.
The peptide prevented and reversed thrombosis in both arterial and venous models, attenuated bleeding and low platelet counts after amputation, and counteracted the effects of both L-NAME and L-arginine on the nitric oxide system. It has already entered clinical trials for ulcerative colitis and multiple sclerosis.
Key Numbers
15 amino acid peptide · Native to human gastric juice · 3-part cytoprotective mechanism · Clinical trials for ulcerative colitis and multiple sclerosis · Thrombosis reversal in arterial and venous models
How They Did This
This is a review article summarizing the authors' extensive body of research on BPC 157. It synthesizes findings from multiple preclinical animal studies examining BPC 157's effects on gastrointestinal healing, vascular protection, thrombosis, bleeding, and organ lesion repair. The review presents a conceptual framework (three-part cytoprotection) for understanding BPC 157's mechanism of action.
Why This Research Matters
BPC 157 extends the concept of 'cytoprotection' — originally limited to stomach lining protection — into a whole-body healing principle. Its ability to protect endothelium, redirect blood vessel growth toward injuries, activate collateral circulation around blockages, and influence thrombosis represents a remarkably broad therapeutic profile for a single peptide. The fact that it's native to human gastric juice and has advanced to clinical trials makes it one of the more intriguing peptides in translational development.
The Bigger Picture
BPC 157 occupies a unique position in peptide research — it's one of the few body-protective peptides that has shown effects across nearly every organ system tested in animals. If its clinical trial results confirm even a fraction of the preclinical findings, it could establish a new category of peptide therapeutics based on the principle of 'cytoprotection' — essentially enhancing the body's own healing mechanisms rather than targeting a specific disease pathway.
What This Study Doesn't Tell Us
The vast majority of evidence comes from animal studies conducted primarily by this single research group. The review is written by BPC 157's discoverers, introducing potential bias. While clinical trials are mentioned (ulcerative colitis, multiple sclerosis), published human efficacy data from these trials is not presented in this abstract. The broad range of claimed benefits across many organ systems is unusual and warrants independent replication. The mechanisms underlying BPC 157's diverse effects are not fully elucidated.
Questions This Raises
- ?Will the clinical trials for ulcerative colitis and multiple sclerosis confirm the broad healing effects seen in animal studies?
- ?What is the specific molecular mechanism by which BPC 157 directs blood vessel growth and activates collateral circulation?
- ?Can independent research groups replicate the wide range of beneficial effects reported by BPC 157's discoverers?
Trust & Context
- Key Stat:
- 3-part cytoprotection BPC 157 protects cells, blood vessel linings, and actively controls blood vessel function at injury sites — extending the stomach cytoprotection concept to the whole body
- Evidence Grade:
- This is a narrative review by the principal BPC 157 research group, summarizing primarily their own preclinical animal data. While clinical trials are referenced, human efficacy data is not presented. The evidence is promising but comes predominantly from one research group.
- Study Age:
- Published in 2018, this review captures the state of BPC 157 research at that time. The status of the referenced clinical trials for ulcerative colitis and multiple sclerosis would need to be checked for current progress.
- Original Title:
- Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.
- Published In:
- Current pharmaceutical design, 24(18), 1990-2001 (2018)
- Authors:
- Sikiric, Predrag(44), Rucman, Rudolf(6), Turkovic, Branko(4), Sever, Marko, Klicek, Robert, Radic, Bozo, Drmic, Domagoj, Stupnisek, Mirjana, Misic, Marija, Vuletic, Lovorka Batelja, Pavlov, Katarina Horvat, Barisic, Ivan, Kokot, Antonio, Peklic, Marina, Strbe, Sanja, Blagaic, Alenka Boban, Tvrdeic, Ante, Rokotov, Dinko Stancic, Vrcic, Hrvoje, Staresinic, Mario, Seiwerth, Sven
- Database ID:
- RPEP-03909
Evidence Hierarchy
Frequently Asked Questions
What is BPC 157 and where does it come from?
BPC 157 (Body Protection Compound 157) is a 15-amino-acid peptide that occurs naturally in human gastric (stomach) juice. It was discovered by Croatian researchers who found it plays a role in maintaining the integrity of the stomach lining. Subsequent research showed it has healing effects far beyond the stomach, affecting blood vessels, tendons, muscles, nerves, and other tissues in animal models.
Is BPC 157 approved as a medication?
As of this review's publication in 2018, BPC 157 had entered clinical trials for ulcerative colitis and multiple sclerosis but was not an approved medication. Most evidence comes from extensive animal studies. While BPC 157 is widely discussed and sometimes sold as a research peptide or supplement, its clinical efficacy and safety in humans have not been fully established through completed trials.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03909APA
Sikiric, Predrag; Rucman, Rudolf; Turkovic, Branko; Sever, Marko; Klicek, Robert; Radic, Bozo; Drmic, Domagoj; Stupnisek, Mirjana; Misic, Marija; Vuletic, Lovorka Batelja; Pavlov, Katarina Horvat; Barisic, Ivan; Kokot, Antonio; Peklic, Marina; Strbe, Sanja; Blagaic, Alenka Boban; Tvrdeic, Ante; Rokotov, Dinko Stancic; Vrcic, Hrvoje; Staresinic, Mario; Seiwerth, Sven. (2018). Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.. Current pharmaceutical design, 24(18), 1990-2001. https://doi.org/10.2174/1381612824666180608101119
MLA
Sikiric, Predrag, et al. "Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.." Current pharmaceutical design, 2018. https://doi.org/10.2174/1381612824666180608101119
RethinkPeptides
RethinkPeptides Research Database. "Novel Cytoprotective Mediator, Stable Gastric Pentadecapepti..." RPEP-03909. Retrieved from https://rethinkpeptides.com/research/sikiric-2018-novel-cytoprotective-mediator-stable
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.